Related Experiment Video
Updated: Sep 9, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Altered Cortical Gyrification, Functional Connections, and Underlying Neurotransmitter Information in Patients with
Qianqian Si1, Caiting Gan1, Xingyue Cao1
1Department of Neurology, The First Affiliated Hospital with Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, China.
Introduction:
The pathogenesis of levodopa-induced dyskinesia (LID) in Parkinson's disease (PD) remains uncertain. Our work sought to examine the cortical gyrification pattern and its corresponding functional connectivity alterations, along with the underlying neurotransmitter information, in LID of PD.
Methods:
We included 30 PD patients with LID (PD-LID group), 30 without LID (PD-NLID group), and 30 age- and gender-matched healthy controls (HC group). Regional cortical gyrification computed by local gyrification index (LGI) and seed-based resting-state functional connectivity (RSFC) were employed. We adopted the JuSpace toolset to further validate whether the spatial patterns in RSFC changes were linked with specific neurotransmitters.
Results:
Compared to PD-NLID, PD-LID demonstrated lower regional LGI in the right inferior frontal gyrus (rIFG) (pars opercularis) and decreased RSFC between the rIFG and the left inferior parietal lobule (IPL). The decreased RSFC was correlated with the spatial distribution of the serotonin transporter (SERT) in the serotonergic system. In particular, the level of rIFG (pars opercularis) LGI was negatively related to the severity of LID and demonstrated good performance in detecting patients with PD-LID.
Conclusion:
Our main findings indicated that the hypogyrification of rIFG and its corresponding functional connectivity reduction with left IPL, as well as the underlying serotonergic neurotransmitter distribution, could underlie the neurobiological underpinnings of LID.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease: Overview
Neural Regulation
Drugs Affecting Neurotransmitter Synthesis

